Purpose of reviewWith 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) as emerging imaging technique offering superior detection rates in biochemical recurrent prostate cancer, salvage lymph node dissection has gained increasing interest in localized oligometastatic prostate cancer. Currently, PSMA-targeting small molecules cannot only be linked to positron-emitting isotopes for imaging but also be labelled with γ-radiation emitting isotopes. These modified PSMA agents are evaluated for intraoperative guidance for resection of metastatic lymph nodes. This review aims to review current knowledge on the novel technique of PSMA-radioguided surgery.Recent findingsRecently radiolabeling of PSMA ligands with 111Indium and 99mTechnetium as γ emitter has been established. After preoperative intravenous injection of these novel PSMA agents single photon emission computed tomography/CT imaging can be performed using the γ-emitting properties. Although its diagnostic performance seems to be inferior to 68Ga-PSMA PET/CT, intraoperative guidance by the use of a γ probe was reported to facilitate detection and resection of tumour-infiltrated soft tissue. First follow-up data suggests favourable outcomes concerning prostate-specific antigen progression and treatment-free survival in a subset of patients.SummaryAlthough current knowledge is still limited and published data is sparse salvage surgery in recurrent prostate cancer facilitated by γ-emitting PSMA agents seems feasible. However, careful identification of ideal candidates for those procedures is mandatory.
Current Opinion in Urology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud